Omnicell, Inc. (NASDAQ:OMCL) Receives $50.67 Average PT from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) have received an average rating of "Hold" from the six ratings firms that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $50.67.

OMCL has been the topic of several analyst reports. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday. Benchmark reissued a "buy" rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Wells Fargo & Company cut their price target on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th.

Omnicell Price Performance

OMCL stock traded down $4.83 during trading on Friday, hitting $25.66. 2,414,675 shares of the company's stock traded hands, compared to its average volume of 543,603. Omnicell has a 52 week low of $23.31 and a 52 week high of $55.75. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 95.04, a P/E/G ratio of 7.53 and a beta of 0.78. The business has a fifty day simple moving average of $33.28 and a 200 day simple moving average of $40.38. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, research analysts expect that Omnicell will post 1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its holdings in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of Omnicell in the 4th quarter worth $37,000. Van ECK Associates Corp grew its position in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Omnicell during the 4th quarter worth $53,000. Finally, First Horizon Advisors Inc. increased its stake in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.